Clinical Trials
Explore current ophthalmic clinical trials investigating emerging treatments for retinal diseases and other vision-threatening eye conditions.
Explore Current Clinical Trials
Valley Retina Institute participates in clinical trials evaluating investigational treatments and new approaches to ophthalmic care. Our studies may provide qualified participants with opportunities to access emerging therapies while contributing to the advancement of vision research.
Our Areas of Research
Our clinical research includes studies involving Wet Age-Related Macular Degeneration, Geographic Atrophy, Uveitis, and emerging retinal and ophthalmic treatments. Available studies and enrollment opportunities change over time as new research becomes available.
Could You Qualify for a Study?
Every clinical trial has specific eligibility requirements based on factors such as diagnosis, medical history, current treatments, and stage of disease. Our research team can help determine whether one of our current studies may be appropriate for you.
Interested in Participating?
Contact Valley Retina Institute to learn more about current clinical research opportunities and whether a study may be right for you.
LIST OF TRIALS ACTIVELY RECRUITING
EYC-0305
NCT07587515
Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Aquarius
NCT07482176
A Multi-center, Randomized, Double-masked, Active-comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
EYETAC
NCT07285070
A Phase 2, Randomized, Double-Masked, Controlled, Proof-of-Concept Study to Evaluate the Safety and Biological Activity of a Water-free Tacrolimus Ophthalmic Solution (NOV05) for the Treatment of Non-Infectious Anterior Uveitis
BI 3812465
NCT07553429
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
SIENNA
NCT06541704
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
ADX-038-202
NCT06990269
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Gallop
NCT07215390
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
ONL1204N
NCT06659445
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Advancing the Future of Eye Care
Our public link: ibcminutes.com/TX00383
Here is a link to the NIH website where it states the rules and regulations:
FAQs About IBC Meetings and Minutes - Office of Science Policy
